MedTrace Logo

PiXL for Correction of Hyperopia

NCT03805425 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-02-03

No results posted yet for this study

Summary

This clinical study aims to investigate the efficacy and safety of PiXL in the refractive correction of low hyperopia.

Conditions

  • Hyperopia

Interventions

RADIATION

PiXL

The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.

Sponsors & Collaborators

  • Gemini Eye Clinic

    lead INDUSTRY

Principal Investigators

  • Pavel Stodulka, MD, PhD · Gemini Eye Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2020-12-31
Completion
2021-03-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03805425 on ClinicalTrials.gov